Vedolizumab
Vedolizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Ulcerative Colitis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
12 项
已进入 III/IV 期
31 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Takeda
- Shilpa Grover, MD, MPH
- Centre Hospitalier Universitaire de Saint Etienne
- University of Alberta
- Janssen Scientific Affairs, LLC
- The Third Xiangya Hospital of Central South University
- University of Nottingham
- University of Calgary
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、法国、加拿大、中国、英国、比利时、Croatia、Czechia、Greece、Israel、意大利、Poland
正在招募患者的 Vedolizumab 研究
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
II 期招募中美国NCT06841705Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
IV 期招募中法国NCT06180382LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
II 期招募中加拿大NCT05327790A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
不适用招募中美国NCT04372108Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study
不适用招募中中国NCT07093294NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
不适用招募中英国NCT06956703A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
III 期招募中比利时CroatiaCzechiaGreeceNCT06443502PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
IV 期招募中加拿大NCT05928039Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
不适用招募中美国NCT06750731Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
不适用招募中奥地利NCT06954311Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
II 期招募中美国NCT06815003High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
不适用招募中美国NCT04331639A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
IV 期招募中美国NCT06581328Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
II 期 / III 期招募中RussiaNCT06756152VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
IV 期招募中美国澳大利亚比利时加拿大NCT06257706Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
II 期招募中澳大利亚奥地利加拿大CzechiaNCT06850727A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
III 期招募中中国NCT05837897Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
IV 期招募中中国NCT05481619Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis
IV 期招募中法国NCT04743518Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
不适用招募中中国NCT07442045Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
IV 期招募中荷兰NCT06031233Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
II 期 / III 期招募中加拿大NCT06337695A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
III 期招募中美国比利时Bulgaria爱尔兰NCT06405087A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
不适用招募中South KoreaNCT05428345
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。